BDPT BioAdaptives Inc

Zeranovia(TM) Weight Loss Product Shows Promising Results in Dosage Trial

Zeranovia(TM) Weight Loss Product Shows Promising Results in Dosage Trial

LAS VEGAS, March 13, 2025 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives Inc. (OTC: BDPT) today announced the successful completion of dosage trials for its innovative weight loss product, Zeranovia™. The trial demonstrated significant weight loss results with minimal side effects, marking a crucial product development milestone.

During the trial, participants experienced weight loss ranging from 5 to 7 pounds per week. Side effects were minimal, with the most common being mild gastrointestinal discomfort, which was easily managed by increasing water intake or adjusting the product dosage.

"We are thrilled with the results of this dosage trial," said James Keener, CEO. "The consistent weight loss across participants, coupled with the manageable side effect profile, indicates that Zeranovia™ has the potential to be a game-changer in the weight loss market."

Key findings from the dosage trial include:

  • Consistent weight loss across participants
  • Minimal side effects, easily managed with simple adjustments
  • High participant satisfaction, with all trial subjects requesting to proceed to the next phase

Based on these promising results, BioAdaptives is moving forward with dosage adjustments for the next stage of clinical trials. The company is optimistic about the product's potential to address the growing global need for effective and safe weight loss solutions.

"The enthusiasm from our trial participants is incredibly encouraging," added Keener. "Their eagerness to continue with the next phase of testing speaks volumes about the product's effectiveness and tolerability."

BioAdaptives is committed to developing innovative solutions for weight management. The company anticipates releasing further updates as the clinical trial progresses.

About BioAdaptives, Inc.

BioAdaptives, Inc. (OTC: BDPT) is a leading innovator in the health and wellness industry. We are dedicated to developing and marketing nutraceutical and wellness products that harness the power of natural ingredients and cutting-edge science. Our mission is to improve the quality of life for our customers by offering products that support optimal health and vitality.

For more information, please visit our website at .

Contact Information:

BioAdaptives, Inc.

Emily Harrison

IR Coordinator

(702)-659-8829



2620 Regatta Dr, Suite 102

Las Vegas, NV 89128

Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among other things, statements regarding expected growth, potential benefits of the company's products, and future business opportunities. These statements involve risks, uncertainties, and other factors that may cause actual results or developments to differ materially from those expressed or implied.

Wire Service Contact:

IBN

Austin, Texas



512.354.7000 Office



EN
13/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioAdaptives Inc

 PRESS RELEASE

Zeranovia(TM) Weight Loss Product Shows Promising Results in Dosage Tr...

Zeranovia(TM) Weight Loss Product Shows Promising Results in Dosage Trial LAS VEGAS, March 13, 2025 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives Inc. (OTC: BDPT) today announced the successful completion of dosage trials for its innovative weight loss product, Zeranovia™. The trial demonstrated significant weight loss results with minimal side effects, marking a crucial product development milestone. During the trial, participants experienced weight loss ranging from 5 to 7 pounds per week. Side effects were minimal, with the most common being mild gastrointestinal discomfort, which was e...

 PRESS RELEASE

BioAdaptives Welcomes UFC Senior Executive Reed Harris to Its Board of...

BioAdaptives Welcomes UFC Senior Executive Reed Harris to Its Board of Advisors Harris, the Senior Vice President of Athlete Development and Marketing at the Ultimate Fighting Championship, has a distinguished career spanning over 40 years LAS VEGAS, Feb. 06, 2025 (GLOBE NEWSWIRE) -- via IBN –  (OTC: BDPT), a leading biotechnology company focused on innovative health and wellness solutions, proudly announces the appointment of Reed Harris to its Board of Advisors. Harris brings decades of experience in leadership, athlete development and business management, and an unparalleled commitme...

 PRESS RELEASE

BioAdaptives Welcomes Mark Frissora, Acclaimed Business Leader, to Its...

BioAdaptives Welcomes Mark Frissora, Acclaimed Business Leader, to Its Board of Directors Frissora is recognized for his ability to lead organizations through complex challenges and deliver sustained value creation LAS VEGAS, Feb. 03, 2025 (GLOBE NEWSWIRE) -- BioAdaptives, Inc. (OTC: BDPT), a pioneering health and wellness company dedicated to innovative, science-driven solutions, is proud to announce the appointment of Mark Frissora to its Board of Directors. Frissora is a visionary leader, celebrated for transforming global brands and driving extraordinary growth at Fortune 500 compan...

 PRESS RELEASE

BioAdaptives Announces FINRA Approval of a Dividend for Common Stock S...

BioAdaptives Announces FINRA Approval of a Dividend for Common Stock Shareholders LAS VEGAS, Jan. 21, 2025 (GLOBE NEWSWIRE) -- via IBN – (OTC: BDPT), a forward-thinking innovator in health and wellness solutions, is pleased to announce that FINRA has approved a dividend to its common stock shareholders. The decision to issue the dividend reflects the company’s gratitude for the unwavering support of its shareholders and their confidence in BioAdaptives’ mission and growth trajectory. Dividends were only paid to common stockholders, not to preferred stockholders. The dividend will be p...

 PRESS RELEASE

BioAdaptives, Inc. Launches Xcellara™ Stem Cell Activator – Harnessing...

BioAdaptives, Inc. Launches Xcellara™ Stem Cell Activator – Harnessing Nature for Optimal Health LAS VEGAS, Dec. 10, 2024 (GLOBE NEWSWIRE) -- via IBN – (OTC: BDPT) is thrilled to announce the launch of Xcellara™ Stem Cell Activator, a groundbreaking supplement that harnesses the extraordinary potential of stem cells' regeneration power through a blend of adaptogens, herbs, and beneficial bacteria. This innovative formulation supports the body's natural repair mechanisms, promoting anti-aging and enhancing overall health and wellness. Xcellara™ Stem Cell Activator has been scientif...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch